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Antibacterial Activity of Sucralfate versus Aluminum Chloride 
in Simulated Gastric Fluid 
L. Welage 1'2., R Carver  1,2, K. Welch 3,4 
Studies have previously demonstrated that sucralfate possesses intrinsic antibacterial 
activity. This study was designed to indirectly assess whether aluminum is the active 
antibacterial component of  sucralfate and to further evaluate factors that may in- 
fluence this agent's antibacterial activity. Utilizing an in vitro model, the antibacterial 
activity of sucralfate, an equivalent quantity of  aluminum in the form of  aluminum 
chloride, and a control were compared. In addition, the influences of bacterial species 
(Enterobacter cloacae and Pseudomonas aeruginosa), time (0-24 h) and environmen- 
tal pH (3, 5, 7) on the agents' antibacterial activities were evaluated. Equivalent quan- 
tities of aluminum, as either sucralfate or aluminum chloride, were added to two of 
three flasks containing approximately 105 cfu/ml of bacteria in pH-adjusted simulated 
gastric fluid. The third flask served as a control. Samples were obtained over 24 h, di- 
luted and subcultured onto agar plates. The experiments demonstrated that bacterial 
growth was influenced by pH, time and treatment (aluminum chloride or sucralfate). 
Regardless of pH or bacterial species, bacterial death occurred within 20 min follow- 
ing the addition of aluminum chloride. In contrast, bacterial death following the addi- 
tion of sucralfate was more variable and appeared to be pH dependent. In conclusion, 
sucralfate and aluminum chloride both possess antibacterial activity, even at pH values 
that normally support bacterial growth in gastric fluid. Although differences in the an- 
tibacterial activity of the two agents may in part be related to drug-induced changes in 
pH, these differences also support data suggesting that aluminum release from sucral- 
fate is incomplete and is dependent on pH. 
Nosocomial pneumonia is an important cause of 
morbidity and mortality in critically ill patients. 
Overall, bacterial pneumonia is the most com- 
mon cause of infection-related death, with mor- 
tality rates as high as 50 % (1, 2). Several investi- 
gators have postulated that increases in gastric 
pH lead to gastric bacterial colonization, which 
may in turn serve as a reservoir for bronchopul- 
monary infections (3-11). Although this view re- 
mains somewhat controversial (3-14), several 
studies have demonstrated that patients receiving 
sucralfate therapy, which does not significantly 
alter gastric pH, have a lower incidence of pneu- 
monia compared to patients receiving antacids or 
H2 receptor antagonists (4, 7, 9). The lower risk of 
pneumonia may, in part, be related sucralfate's 
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ability to maintain the normal gastric acid bacte- 
ricidal barrier. However, studies have also shown 
that the incidence of gastric bacterial colonization 
and subsequent pneumonia during sucralfate 
therapy remains low despite many patients 
having gastric pH values of > 4.0 (4, 7, 9). Thus, 
sucralfate appears to possess some intrinsic anti- 
bacterial activity. This hypothesis has been con- 
firmed in vitro; sucralfate demonstrates marked 
antibacterial activity against Escherichia coli, 
Klebsiella pneumoniae, Staphylococcus aureus 
and Pseudomonas aeruginosa (15-17). 
Although it is recognized that sucralfate, a basic 
aluminum salt of sucrose octasulfate, possesses 
antibacterial properties, the active component of 
sucralfate has not yet been identified. Since it is 
well recognized that many metals, including mer- 
cury and bismuth, have antibacterial activity, we 
postulated that the aluminum component of 
sucralfate may be the active moiety responsible 
for its antibacterial activity (18, 19). Since alu- 
minum release from sucralfate is pH dependent, 
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we fur ther  hypo thes i zed  that  sucralfate 's  anti- 
bacterial  activity would  be inf luenced by the p H  
o f  the gastr ic  fluid (20, 21). This compara t ive  
s tudy was p e r f o r m e d  to  charac ter ize  the in- 
f luence o f  p H  and  bacter ia l  species on sucralfate 's  
ant ibacterial  activity and to ascertain whether  
a luminum possesses  ant ibacter ia l  activity. Spe- 
cifically, this s tudy  was des igned to c o m p a r e  the 
ant ibacter ia l  act ivi ty o f  sucralfate ,  an equivalent  
a m o u n t  o f  a luminum in the  f o r m  of  a luminum 
chloride and  con t ro l  against  two c o m m o n  gram-  
negat ive pa thogens .  Since p H  and  time m a y  in- 
f luence bacter ia l  g rowth ,  ant ibacter ia l  activity 
and a l u m i n u m  release  f rom the agents ,  serial ex- 
per iments  were  conduc t ed  in s imulated gastric 
fluid at p H  values  3, 5 and 7 over  a 24 h s tudy pe- 
riod. 
Materials and Methods 
In order to simulate clinical conditions, t g sucralfate 
tablets (Carafate, lot no. $8460, Marion Laboratories, 
USA) and an equivalent amount of aluminum (206.9 rag) 
m the form of 1.022 g aluminum chloride (EM Industries, 
USA) were used in all experiments. Simulated gastric 
fluid was prepared according to the United States Phar- 
macopeia formulation (USP XXI-NF XVI; U.S. Phar- 
.rnacopoeial Convention, Rockville, MD, 1985) and ad- 
Justed to the desired pH (3, 5 or 7) just prior to each 
experiment by the addition of aqueous 1.0 M or 2.0 M 
Sodium hydroxide (lot no. 7689 KELM, Mallinckrodt, 
USA) or hydrochloric acid (lot no. 3560 KBBK, Mal- 
linckrodt) (22). The pH was measured using a pH meter 
(Orion Research Digital Ionalyzer/501) calibrated to 
pFI 4 and pH 7 with standardized phosphate buffer so- 
lutions (VWR Scientific, USA). 
Pseudomonas aeruginosa (ATCC 27853) and Entero- 
bacter cloacae (ATCC 13047) were obtained from the 
American Type Culture Collection (RockviUe, MD). 
These organisms were selected as the test organisms be- 
cause they are frequently implicated as pathogens in no- 
SOcornial pneumonia and are often difficult to eradicate. 
l~aeterial cultures were prepared by inoculating 5 ml of 
Mueller.Hinton broth (Difco Laboratories, USA) with 
5 efu of bacteria from a stock plate and incubating the 
broth inoculum for 18 to 24 h at 37°C. Overnight broth 
cultures containing approximately 109 cfu/ml were serially 
diluted with Mueller-Hinton broth and plated on 
Mueller-Hinton agar (Difco Laboratories) to confirm the 
number of organisms present in the culture and to quan- 
tify the baseline inoculum used in each experiment. 
Experimental Design. On each day of the experiments, 
50 rnl of pH-adjusted simulated gastric fluid and a mag- 
netic stirrin~ bar were added to three sterile Erlenmeyer 
flasks, whic~a were subsequently inoculated with 0.5 ml 
of the overnight culture of bacteria (Pseudomonas aeru- 
ginosa or Enterobacter cloacae) to produce a final bacte- 
rial concentration of approximately 105 cfu/ml. A time 
Zero sample was obtained from each flask and serially 
diluted in Mueller-Hinton broth, and 0.1 ml samples of 
the dilutions were cultured in duplicate on Mueller-Hin- 
ton agar plates. Subsequently, the flasks were treated 
with either 1 g sucralfate, 1.022 g aluminum chloride or 
no drug (control). Samples were obtained from each flask 
at 0.33, 0.67, t, 2, 4, 6, 8, 12 and 24 h and serially diluted 
with Mueller-Hinton broth. 0.I ml samples of the dilu. 
tions were cultured in duplicate on Mueller-Hinton agar, 
Colony counts were determined by the spread plate tech- 
nique, in which the sample was pipetted onto the surface 
of solidified Mueller-Hinton agar in a petri dish and the 
cells distributed with a wire. Bacterial colonies were 
manually quantified on each plate following overnight 
incubation at 37°C. Experiments were performed in trip- 
licate at each of the desired pH values (3, 5 and 7) with 
each of the test organisms. 
Statistical Analyses. Initial bacterial inoculums for each 
of the experiments were compared using a two-way analysis 
of variance utilizing the Statistica software package (Star. 
soft, USA) (CCS:Statistica Volume I-III, Statsoft, USA, 
1991). Percent reductions in tog cfu/ml were determined 
based on the log cfu/ml prior to the addition of the agents 
(time zero) minus the log cfu/ml at each timepoint divided 
by log cfu/ml at time zero and multipled by 100. Bacterial 
killing curves were constructed by plotting log bacterial 
cfu/mI versus time for each of the conditions. The rates 
of kill for the two treatments (aluminum chloride and 
sucralfate) were determined from the slopes of the log 
bacterial concentration versus time profiles. Differences 
in killing rates between the two treatments were eval- 
uated with a two-way analysis of variance. Other factors 
in the model included pH and bacterial species. Post hoc 
comparisons were performed using Tukeys contrast 
method. Significance was defined as a p value of < 0.05. 
Data are represented as the mean + one standard devia- 
tion, unless otherwise stated. 
Initially, comparisons in the log number of cfu/ml for each 
treatment, pH and timepoint were to be made utilizing 
analysis of variance. However, since a critical assumption 
for the analysis of variance (i.e. equal variance among 
groups) could not be met, a Bayesian analysis was utilized 
(22). The probability that all of the cfu/ml in a given 
treatment-pH combination would die before the end of 
the study period given the probability of dying for each 
treatment-pH combination was modelled, The Bayesian 
analysis used the distribution of the data from the ex- 
periment along with the prior probability of dying (as- 
sumed to be uniform for all treatment-pH combinations) 
to determine the posterior probability of dying (i.e. the 
updated probability of dying, given the observed data). 
The posterior distributions of the probability of dying 
were then compared for each treatment-pH combination 
to determine if there were any significant differences. 
The posterior probability of dying in each ceil of the 
study design is distributed as a beta distribution, with 
parameters k-I and n-k-l, where n is the total number of 
flasks in the cell and k is the number of flasks in the cell 
in which all colonies died. The MIDAS (Michigan Inter- 
active Data Analysis System) computer program was 
used to generate 10,000 cases of a simulated beta dis- 
tribution that could be used to compare the probability 
of dying for the different treatment-pH combinations. 
This analysis permitted direct comparison of the prob- 
abilities that the given treatment-pH combinations would 
kill all of the colony-forming units within the 24 h study 
period. 
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Results 
The initial broth cultures used to inoculate the 
simulated gastric fluid contained 108 to 
109 cfu/ml. The mean log cfu/ml broth inoculums 
for Enterobacter cloacae were 9.39 + 0.44, 9.36 
_+ 0.02 and 9.16 + 0.35 for pH values 3, 5 and 7, re- 
spectively, and were not significantly different 
from one another. Similarly, the mean log cfu/ml 
broth inoculums for Pseudomonas aeruginosa 
were 9.42 + 0.03, 9.39 + 0.16, and 9.48 + 0.19 for 
pH values 3, 5 and 7, respectively (p > 0.05). Since 
baseline broth inoculums were not significantly 
different between the individual experiments, the 
inoculum was not used as a covariate in sub- 
sequent analyses. 
As shown in Figure 1, bacterial growth for Entero- 
bacter cloacae and Pseudomonas aeruginosa in 
the absence of sucralfate or aluminum chloride 
was significantly influenced by the pH of the en- 
vironment. As anticipated, bacterial concentra- 
tions were significantly greater over time at the 
higher pH values. The addition of aluminum 
chloride or sucralfate resulted in dramatic bacte- 
rial killing. The organisms were significantly 
more likely to be dead at 24 h following the addi- 
tion of aluminum chloride or sucralfate as com- 
pared to control. However, when the aluminum 
chloride and sucralfate treatments were com- 
pared by Bayesian methods, no significant differ- 
ences were detected in the probability of all or- 
ganisms dying within the 24 h study period. As 
shown in Figures 2 and 3, the addition of alum- 
inum chloride resulted in rapid bacterial eradica- 
tion that was independent of pH or organism. 
Death of all organisms occurred within 20 min 
following the addition of the aluminum chloride 
at all pH values studied. Conversely, following the 
addition of sucralfate, the rate of bacterial death 
was much slower and more variable and appeared 
to be influenced by pH. 
The mean rates of bacterial killing for Entero- 
bacter cloacae were 0.39 + 0.14,1.2 + 0.72 and 0.99 
+ 0.77 h -1 at pH 3, 5 and 7, respectively, following 
the addition of sucralfate and were significantly 
slower than those seen following the addition of 
aluminum chloride (15.52 + 1.98, 15.99 + 0.76 and 
15.80 + 1.89 h -1 at pH 3, 5 and 7, respectively). 
Similarly, the mean rates of bacterial killing for 
Pseudomonas aeruginosa were 1.38 + 0.36, 0.44 
+ 0.06 and 0.44 + 0.09 h "1 following the addition of 
sucralfate as compared to 16.18 + 0.18, 15.09 
+ 1.69 and 16.43 + 0 h  -1 at pH 3, 5 and 7, respec- 
tively, following the addition of aluminum 
chloride (p < 0.05). The mean rate of bacterial 
death was significantly different for the two treat- 
ment regimens (aluminum chloride versus sucral- 
fate) but was not significantly influenced by 
bacterial species or pH. 
The addition of either sucralfate or aluminum 
chloride to simulated gastric fluid resulted in dra- 
matic changes in the pH of the solutions. The ad- 
dition of i g of sucralfate to 50 ml of simulated ga- 
stric fluid with an initial pH of 3, 5 or 7 resulted in 
solutions with pH values of 4.31, 4.77 and 5.07, re- 
spectively. The addition of 1.022 g of aluminum 
chloride to 50 mI of simulated gastric fluid with a 
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Figure la: Mean log bacterial cfu/ml over time for Entero- 
bacter cloacae at pH 3 (4,), 5 (A) and 7 (111) in the absence of 
aluminum chloride or sucralfate (control). 
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Figure lb: Mean log bacterial cfu/ml over time for Pseudo- 
monas aeruginosa at pH 3 (IP), 5 (A) and 7 ( i )  in the absence 
of aluminum chloride or sucralfate (control), 
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pH of 3, 5 or 7 resulted in final pH values of the so- 
lutions of 3.31, 3.27 and 3.33, respectively. 
Discuss ion 
This study demonstrates that both sucralfate and 
aluminum chloride possess marked antibacterial 
activity against Enterobacter cloacae and Pseudo- 
rnonas aeruginosa. Sucralfate's antibacterial ac- 
tivity was variable and appeared to be pH de- 
pendent; however, this trend did not reach statis- 
tical significance. Conversely, bacterial death 
rates following the addition of aluminum chloride 
were rapid and, on superficial inspection, ap- 
peared to be independent of pH. However, it is 
important to recognize that the pH of the solution 
following the addition of aluminum chloride was 
approximately 3.3, regardless of the initial pH  (3, 
5 or 7). Although pH changes were also observed 
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gure 2: Mean percent reduction in log cfu/ml from baseline 
o) over time for Enterobacter cloacae at pH 3, 5 and 7 for 
SUcralfate (11), aluminum chloride (4,) and no drug (control! 
(&). Co is the initial bacterial inoculum of the simulated g,,,~-,~' " 
fluid. 
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]Figure 3: Mean percent reduction in log ~u/m| from baseline 
(Co) over time for Pseudomon~ acruginosa at pH 3, 5 and 7 
for sucralfate (I D, aluminum chloride (@) and no drug (con- 
trol) (&). Co is the initial bacterial inoculum of the simulated 
gastric fluid. 
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following the addition of sucralfate, these 
changes were less dramatic and were of a magni- 
tude similar to those observed by other investiga- 
tors (15-17). Since both agents influenced pH, we 
cannot fully assess the influence of pH on the 
agents' antibacterial activities. 
Previous studies utilizing a variety of methodolo- 
gies have demonstrated that sucralfate possesses 
antibacterial activity against Klebsietla pneu- 
moniae, Escherichia coli, Staphylococcus aureus 
and Pseudomonas aeruginosa (15-17). Data sug- 
gests that the degree of antibacterial activity is de- 
pendent upon the bacterial species; antibacterial 
activity against Pseudomonas aeruginosa is less 
than that against other gram-negative organisms 
(15-17). Our data demonstrates that sucralfate 
also possesses marked antibacterial activity 
against Enterobacter cloacae, a common respira- 
tory pathogen in critically ill patients. At pH 
values 5 and 7, bacterial killing following the ad- 
dition of sucralfate was more rapid for Enter- 
obacter cloacae than for Pseudomonas aerugi- 
nosa. This finding further supports the concept 
that sucralfate's antibacterial activity against 
Pseudomonas aeruginosa is less than that against 
other gram-negative organisms. 
Direct comparison of our results to those found in 
the literature is difficult due to the numerous 
methodologies employed (15-17, 23). For ex- 
ample, Goeger et al. (23) demonstrated bacterial 
growth of Pseudomonas aeruginosa, Escherichia 
coil and Staphylococcus aureus at pH values 3, 4 
and 6 in the presence of sucralfate. On the basis of 
these findings, the authors concluded that sucral- 
fate promotes bacterial growth. These findings 
are in direct contradiction to our results as well as 
those of Tryba and Mantey-Stiers (15), Kappstein 
and Engels (16) and Daschner et al. (17). A 
potential explanation for these disparate results is 
the media used (15-17, 23). Goeger et al. (23) util- 
ized a bicarbonate solution that contained pepsin 
(with or without the addition of milk). Other in- 
vestigators, including ourselves, have utilized 
simulated gastric fluid, which yields results simi- 
lar to those observed by Tryba and Mantey-Stiers 
(15), who utilized human gastric fluid (15-17). 
Two additional differences between our study de- 
sign and others are the size of the bacterial in- 
oculum and the concentration of sucralfate em- 
ployed (15-17, 23). Our study utilized higher ini- 
tial bacterial inoculums (105 cfu/ml) than have 
previously been reported. Although previous stu- 
dies have assessed the antibacterial activity of so- 
lutions containing 1.5, 2.5 and 5 % sucralfate, we 
chose to evaluate the activity of a 2 % sucralfate 
solution (1 g/50 ml) (16, 17, 23). We intentionally 
chose to assess the antibacterial activity of a usual 
therapeutic dose of sucralfate (1 g) in a small fluid 
environment (i.e. 50 ml of simulated gastric fluid). 
Despite using higher initial inoculums and a 
different concentration of sucralfate, we obtained 
results similar to those of Kappstein and Engels 
(16), who utilized a similar study design. 
It has long been recognized that a variety of metal 
and organometallic compounds can inhibit the 
growth of bacteria, fungi and parasites. Although 
widespread clinical use of metals and or- 
ganometallic compounds has been hampered by 
their toxic effects on humans and the develop- 
ment of resistant bacteria, recent studies have fo- 
cused on the synthesis of less toxic agents with 
potent antibacterial activity (24). For example, 
dental prosthetic materials that contain silver, 
zinc, copper, fluoride and mercury have been 
shown to have antibacterial activity against a 
wide variety of oral flora (25). Similarly, the incor- 
poration of silver into the polymer matrix of in- 
travenous or urinary catheters is beneficial in 
decreasing the local concentrations of bacteria 
and may prove useful in decreasing the incidence 
of catheter-related infections (26). The antibacte- 
rial activity of bismuth has been studied both in 
vitro and in human subjects for the treatment of 
duodenal ulcers associated with Helicobacter py- 
lori (19, 27). 
Since sucralfate is a basic aluminum salt of 
sucrose octasulfate and metals are known to 
possess antibacterial activity, we hypothesized 
that aluminum was the active component re- 
sponsible for sucralfate's antibacterial activity. In 
order to indirectly assess this, we evaluated the 
antibacterial activity of an equivalent quantity of 
aluminum (206.9 rag) when administered as 
aluminum chloride. Aluminum chloride was 
chosen because it is soluble in aqueous media and 
should completely dissociate to aluminum plus 
hydrochloric acid (28). This agent would there- 
fore allow assessment of the antibacterial activity 
of the maximum amount of aluminum (206.9 mg) 
that could theoretically be released from sucral- 
fate. On the basis of the pH changes observed fol- 
lowing the addition of aluminum chloride, we 
strongly believe that aluminum completely disso- 
ciated from the agent. In addition, we believe that 
the antibacterial activity observed after the addi- 
tion of aluminum chloride is the result of the free 
aluminum and not solely the result of the pH 
changes induced by the addition of the aluminum 
chloride. The addition of aluminum chloride re- 
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suited in a p H  of approximately 3.3. However,  
bacterial death was far more  rapid in the alu- 
minum chloride solutions than in the control solu- 
tions at pH  3. 
It is also clear f rom our results that sucralfate's an- 
tibacterial activity is slower and more  variable 
than that observed with aluminum chloride. We 
believe this reflects the fact that aluminum does 
not complete ly  dissociate from sucralfate and 
therefore is not  completely available to exert  an 
antibacterial effect. Previous studies have shown 
that the release of aluminum from sucralfate is 
pH dependent ,  with a greater  amount  of  alu- 
minum being released at lower pH values (21). It 
is difficult to separate  the influence of  p H  on 
aluminum release and subsequent bacterial death 
from the influence of  pH  alone on bacterial death. 
Theoretically, one  could at tempt  to assess the an- 
tibacterial activity of the agents independent  of 
pH by titrating the simulated gastric fluid to the 
initial pH. However ,  this would not accurately re- 
flect the clinical situation. In addition, titrating 
the simulated gastric fluid to the initial pH level 
may theoretically alter the amount  of  aluminum 
available. 
Although our data demonstra te  that aluminum 
chloride possesses marked antibacterial activity, 
this does not appear  to be the case for other alu- 
minum-containing products. Tryba and Mantey- 
Stiers (15) demonstra ted that an antacid contain- 
ing aluminum hydroxide, magnesium hydroxide 
and calcium carbonate  did not  have antibacterial 
activity against Escherichia coli and Pseudo- 
monas aeruginosa. On the basis of their findings, 
one may conclude that aluminum does not 
possess antibacterial activity; however, we postu- 
late that little or no aluminum is released from the 
insoluble antacid to subsequently be available to 
exert an antibacterial effect (28). Alternatively, 
the dose of antacid may not  have been sufficient 
to provide antibacterial activity. 
Our findings clearly demonstrate that both sucral- 
fate and aluminum chloride possess marked anti- 
bacterial activity. Since we were unable to test the 
antibacterial activity of the sucrose octasulfate 
POrtion, we cannot  directly conclude that alum- 
Inum is the active antibacterial component  of 
SUcralfate. However,  the striking antibacterial ac- 
tivity observed with aluminum chloride demon- 
Strates that aluminum possesses antibacterial ac- 
tivity. On the basis of these data, we infer that 
aluminum is the active antibacterial component  
of SUcralfate. The  antibacterial activity of sucral- 
fate may be pH  dependent ,  secondary to the in- 
fluence of pH on aluminum release as well as the 
influence of pH on bacterial growth. Although 
this hypothesis cannot be completely evaluated in 
our study due to sucralfate-induced alterations in 
pH, it could be evaluated in future trials by meas- 
uring aluminum concentrations and correlating 
these concentrations with antibacterial activity. In 
summary, we suggest that aluminum is the active 
antibacterial moiety in sucralfate. Therefore ,  
aluminum may be responsible for  the lower inci- 
dence of  gastric bacterial colonization and pneu-  
monia observed in several clinical trials compar-  
ing sucralfate, antacids and H2 receptor  antago- 
nists (4, 7, 9). 
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